Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy. Li X, Zhang D, Li B, Zou B, et al. Lung Cancer 2021;151:39-43.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li X, Zhang D, Li B, Zou B, et al. Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy. Lung Cancer 2021;151:39-43.
PMID: 33296806